Effect of karelizumab combined with chemotherapy on cellular immunity and angiogenic factors in patients with intermediate and advanced NSCLC
Objective To investigate the effects of karelizumab combined with chemotherapy on cellular immunity and angiogenic factors in patients with intermediate and advanced non-small cell lung cancer(NSCLC).Methods Eighty-six patients with intermediate and advanced NSCLC who attended our hospital from May 2020 to May 2023 were se-lected and divided into a control group(43 cases,treated with chemotherapy),and a study group(43 cases,treated with chemotherapy+karelizumab)according to the principle of randomised control,and were treated for a total of 3 cy-cles.The clinical efficacy,tumor markers[soluble fragment of cytokeratin 19(Cyfra21-1),carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA)],angiogenic factors[vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)]and immune function[CD4+,CD3+,CD8+]were compared between the two groups.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)of the study group were higher than those of the control group(P＜0.05);Compared with the control group,the serum levels of Cy-fra21-1,CA125,CEA,VEGF and bFGF in the study group decreased significantly after treatment(P＜0.05).Com-pared with the control group,the levels of CD4+,CD3+,CD4+/CD8+ in the study group increased significantly after treatment,while the level of CD8+decreased significantly(P＜0.05).The incidence of adverse reactions in the study group and the control group during the treatment was similar(P＞0.05).Conclusion The efficacy of karelizumab com-bined with chemotherapy in the treatment of intermediate and advanced NSCLC is precise,which can effectively improve the immune function of patients,reduce the levels of tumour markers and angiogenic factors,and will not increase the incidence of adverse reactions,so the clinical efficacy is better.
NETL
NSTL
万方数据
